CN104220073A - Ccr3-抑制剂的用途 - Google Patents

Ccr3-抑制剂的用途 Download PDF

Info

Publication number
CN104220073A
CN104220073A CN201380016333.7A CN201380016333A CN104220073A CN 104220073 A CN104220073 A CN 104220073A CN 201380016333 A CN201380016333 A CN 201380016333A CN 104220073 A CN104220073 A CN 104220073A
Authority
CN
China
Prior art keywords
eosinophilic
treatment
alkyl
compound
chloride ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380016333.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·C·尼文斯
T·博伊苏
R·戈格尔
P·赛斯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evergreen Springs
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104220073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to CN201910406245.7A priority Critical patent/CN110384699A/zh
Publication of CN104220073A publication Critical patent/CN104220073A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Structure Of Transmissions (AREA)
CN201380016333.7A 2012-04-03 2013-04-02 Ccr3-抑制剂的用途 Pending CN104220073A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910406245.7A CN110384699A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937.2 2012-04-03
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910406245.7A Division CN110384699A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途

Publications (1)

Publication Number Publication Date
CN104220073A true CN104220073A (zh) 2014-12-17

Family

ID=48040249

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380016333.7A Pending CN104220073A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途
CN201910406245.7A Pending CN110384699A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910406245.7A Pending CN110384699A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP3763369B1 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20140144200A (enExample)
CN (2) CN104220073A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110650740A (zh) * 2017-04-05 2020-01-03 万能溶剂有限公司 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11045284B2 (en) 2016-11-24 2021-06-29 Kirishima Seiko Co., Ltd. Dental brace and method for attaching dental brace
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
US20190111042A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
US20230312697A1 (en) 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
BRPI0108923B8 (pt) * 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110650740A (zh) * 2017-04-05 2020-01-03 万能溶剂有限公司 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物
US11590118B2 (en) 2017-04-05 2023-02-28 Alkahest Inc. Methods and compositions for treating retina-associated disease using CCR3-inhibitors
US11951102B2 (en) 2017-04-05 2024-04-09 Alkahest Inc. Methods and compositions for treating retina-associated disease using CCR3-inhibitors

Also Published As

Publication number Publication date
PT2833884T (pt) 2020-08-26
EP4389217A2 (en) 2024-06-26
US20200375971A1 (en) 2020-12-03
ES2811554T3 (es) 2021-03-12
HUE051648T2 (hu) 2021-03-29
HRP20201165T1 (hr) 2020-12-11
SMT202000499T1 (it) 2020-11-10
IL234262A (en) 2017-10-31
US20160081998A1 (en) 2016-03-24
RS60665B1 (sr) 2020-09-30
EP2833884B1 (en) 2020-05-20
AU2013245027B2 (en) 2017-10-12
EP3763369B1 (en) 2024-02-28
KR20200044988A (ko) 2020-04-29
NZ628882A (en) 2016-05-27
US20130261153A1 (en) 2013-10-03
CA2869269C (en) 2020-06-30
EP2833884A1 (en) 2015-02-11
PH12014502239A1 (en) 2014-12-15
ES2987267T3 (es) 2024-11-14
EP3763369A1 (en) 2021-01-13
IN2014DN06989A (enExample) 2015-04-10
KR20220132012A (ko) 2022-09-29
EA201401083A1 (ru) 2015-03-31
CY1123222T1 (el) 2021-10-29
AU2013245027A1 (en) 2014-09-11
BR112014023795A8 (pt) 2017-10-10
LT2833884T (lt) 2020-09-10
ZA201406082B (en) 2019-01-30
US20170319567A1 (en) 2017-11-09
CL2014002523A1 (es) 2015-01-23
EA032263B1 (ru) 2019-05-31
EP4389217A3 (en) 2024-08-28
US20150099783A1 (en) 2015-04-09
CN110384699A (zh) 2019-10-29
PL2833884T3 (pl) 2020-11-02
KR20250133980A (ko) 2025-09-09
DK2833884T3 (da) 2020-08-10
BR112014023795A2 (enExample) 2017-06-20
WO2013149986A1 (en) 2013-10-10
CA2869269A1 (en) 2013-10-10
KR20140144200A (ko) 2014-12-18
BR112014023795B1 (pt) 2021-09-08
JP2015512432A (ja) 2015-04-27
MX2014011786A (es) 2014-12-05
KR20210063481A (ko) 2021-06-01
SI2833884T1 (sl) 2020-10-30
JP2018080183A (ja) 2018-05-24

Similar Documents

Publication Publication Date Title
CN104220073A (zh) Ccr3-抑制剂的用途
JP6700332B2 (ja) Ｃｃｒ３アンタゴニストを含む医薬製剤
CN1235545A (zh) 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
JP7588773B2 (ja) グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用
HK40015701A (en) Use of ccr3-inhibitors
WO2004034973A2 (en) Method of treating snoring and other obstructive breathing disorders
WO2016006621A1 (ja) Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物
CN1897952B (zh) 中性白细胞增多抑制剂
JP2005522462A (ja) 気道疾患の治療のためのプロトンポンプ阻害剤の使用
AU2006283702A1 (en) Comination of a hypnotic agent and R(+)-alpha-(2,3-dimethoxy-phenyl)-1-(2-(4-fluorophenl)ethyl)-4-piperidinemethanol and therapeutic application thereof
HK1261581B (zh) 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途
JP2010111666A (ja) セチリジンを含有する鎮咳及び／又は去痰のための医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170323

Address after: American California

Applicant after: Evergreen springs

Address before: In Germany

Applicant before: Boehringer Ingelheim Int

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20141217

RJ01 Rejection of invention patent application after publication